Depo-Provera Brain Tumor Symptoms Reported Among Birth Control Users

Women now pursuing lawsuits over meningiomas diagnosed after Depo-Provera injections describe years of neurological symptoms, specialist visits, brain scans, and in some cases invasive surgery.

Millions of women who relied on Depo-Provera for birth control are now facing growing fears that the injection may have caused meningioma brain tumors, as new research, an FDA warning update, and thousands of Depo-Provera lawsuits raise serious questions about the long-term safety of the popular contraceptive shot.

In recent months, the controversy surrounding Depo-Provera has intensified as regulators, researchers and courts examine evidence linking prolonged exposure to the drug’s synthetic hormone to tumor growth in the brain. These developments have drawn renewed attention to the potential Depo-Provera meningioma side effects associated with long-term use of the injection.

At the same time, thousands of women who were diagnosed with intracranial meningiomas after receiving Depo-Provera injections are now pursuing lawsuits against the manufacturers, each claiming they were never warned that repeated injections could potentially increase the risk of developing hormone-sensitive brain tumors.

For the millions of current and former Depo-Provera users, emerging evidence has sparked new questions about whether symptoms like persistent headaches, vision changes, dizziness or memory problems could signal an undiagnosed meningioma that developed years after receiving the injections.

Many of the women impacted by Depo-Provera have shared their experiences on this website, as well as other online forums and social media platforms, describing potential brain tumor symptoms from Depo-Provera, and expressing fear that their current, or past use of the birth control shot may leave them susceptible to developing a meningioma.

In this featured post, AboutLawsuits.com will explore the growing concerns surrounding Depo-Provera use, highlight symptoms that have been reported by women, and explain allegations in personal injury lawsuits now being pursued to hold the manufacturers accountable.

Does Depo-Provera Cause Brain Tumors?

Depo-Provera has been widely used for decades as a long-acting birth control injection, delivering the synthetic hormone medroxyprogesterone acetate to prevent pregnancy for up to three months per dose. However, a growing body of research now links prolonged exposure to the drug with an increased risk of intracranial meningioma tumors.

Meningiomas are hormone-sensitive tumors that form in the membranes surrounding the brain and spinal cord, and scientists believe Depo-Provera’s synthetic hormone may stimulate abnormal cell growth in some patients.

In recent years, several major developments have intensified concerns about the contraceptive shot, including a new FDA warning, large epidemiological studies and mounting evidence of elevated tumor risks.

FDA Finally Adds Depo-Provera Meningioma Warning

One of the most significant developments in recent months came when the U.S. Food and Drug Administration approved a long-awaited update to the Depo-Provera warning label, officially acknowledging the potential risk of meningioma brain tumors.

The updated prescribing information now warns that:

“Cases of meningiomas have been reported following repeated administration of medroxyprogesterone acetate, primarily with long-term use. Monitor patients on Depo-Provera for signs and symptoms of meningioma.”
–U.S. Food and Drug Administration

The label update also instructs physicians to discontinue Depo-Provera if a patient is diagnosed with a meningioma.

The warning applies to both injectable forms of the contraceptive, Depo-Provera CI and Depo-SubQ Provera 104, which both contain the same active ingredient, medroxyprogesterone acetate.

For many women and attorneys pursuing litigation, the FDA’s action represents a major shift. For decades, Depo-Provera was sold in the United States without any warning about brain tumor risks, despite mounting scientific evidence linking long-term exposure to an increased likelihood of developing meningiomas.

Studies Link Depo-Provera to Increased Meningioma Risk

Several major studies published over the last two years have raised concerns that long-term exposure to medroxyprogesterone acetate may increase the risk of developing intracranial meningioma tumors.

Taken together, researchers say these findings add to a growing body of evidence suggesting that long-term exposure to synthetic progestins like medroxyprogesterone acetate may stimulate the growth of hormone-sensitive brain tumors.

YOU MIGHT BE INTERESTED IN…

Depo-Provera Meningioma Brain Tumors Risks May Have Been Ignored by Pfizer for Decades

After decades of medical research and reported Depo-Provera side effects, Pfizer should have known that its birth control shot increases the risks of meningioma brain tumors, yet failed to warn women or the medical community.

Read More

Understanding Depo-Provera Brain Tumor Symptoms

It can be easy to dismiss frequent headaches or occasional dizziness as stress or the demands of a busy lifestyle. However, for some women, these seemingly harmless symptoms may indicate a far more serious underlying condition such as meningiomas, tumors that develop in the protective layers surrounding the brain and spinal cord.

While meningiomas are often benign and slow-growing, they can still lead to serious health complications depending on their size, growth rate and location. In many cases, the tumors remain asymptomatic in the early stages, making them difficult to detect. Over time, however, they can gradually enlarge, causing symptoms that may go unnoticed or be misattributed to other common health concerns.

Common Depo-Provera Brain Tumor Symptoms

Women who are still taking Depo-Provera, or previously received courses of the Depo-shot, may unknowingly be at risk for meningiomas, with symptoms that can slowly interfere with daily life and overall well-being.

As these tumors grow, they can exert pressure on surrounding brain structures, leading to a range of symptoms, including:

• Headaches: Persistent or worsening headaches that do not respond to usual treatments.
• Vision disturbances: Blurred vision, double vision or vision loss in one or both eyes.
• Hearing loss: Gradual or sudden hearing impairment, often accompanied by ringing in the ears (tinnitus).
• Memory problems: Difficulty with concentration, forgetfulness or noticeable cognitive decline.
• Dizziness and balance issues: Frequent vertigo, unsteadiness or coordination difficulties.
• Seizures: Sudden, unexplained seizures or unusual neurological activity.
• Fatigue: Persistent tiredness that does not improve with rest and affects daily activities.
• Speech difficulties: Slurred speech or trouble finding the right words in conversation.
• Nausea and vomiting: Unexplained gastrointestinal symptoms that persist without an obvious cause.

Real Stories of Depo-Provera Brain Tumor Symptoms

For many women, the potential link between Depo-Provera and meningiomas is more than just a health concern, it is a reality they face every day.

On AboutLawsuits.com, numerous former Depo-Provera users have shared their personal experiences, describing symptoms that mirror those associated with meningiomas, highlighting the significant impact this condition has had on their lives.

Personal Accounts of Depo-Provera-Related Brain Tumor Symptoms

• Tammy ( December 1, 2025): “Took Depo-Provera injections for approx 4 years, 93-97/98… I wake up with worse headache EVER, lite headed, chest pain, left eye turned completely dark/black. Husband called ambulance. Went to ER. Was stabilized after 3-4 hours. CAT scan showed tumor… Tumor is wrapped around nerves and arteries, wrapped around left optical nerve and pressing on my spine.”

• Victoria (September 28, 2025): “I’ve been using depot since I was 24 years old. Religiously like I’ve never stopped and I’m now 49. I’ve had extremely bad migraines and my eyesight is declined by a lot. My fear is that my migraines are a result of a brain tumor I have attempted to go to the ER to get my brain scan but was denied. So I haven’t had any medical evaluations.”

• Carlyne (May 11, 2025): “I’ve been experiencing headaches, vision problems, nausea and imbalance, memory loss, and confusion.”

• Roxanne (December 14, 2024): “I’ve experienced severe headaches and dizziness, to the point where even the slightest angle of my head being below my heart makes me feel dizzy—even while lying down. I also struggle with instability when walking and memory loss.”

• Gracie (November 7, 2024): “I developed a meningioma tumor that caused me to lose my hearing. It grew dangerously close to my hearing nerve.”

• Kelly (September 13, 2024): “I’ve been dealing with headaches, vision problems, nausea, imbalance, memory loss, and swelling with fluid buildup on the back left side of my skull.”

• Lyndsie (December 15, 2024): “I used Depo-Provera for just one year in 2003, and soon after, I developed extremely high blood pressure. The pressure headaches behind my eyes have persisted for 20 years, and I still haven’t been diagnosed.”

These firsthand accounts highlight the urgent need for women who have taken Depo-Provera to receive medical scans and ongoing monitoring to detect meningiomas early, and track their growth for proper intervention.

Medical Testing and Treatment Described in Depo-Provera Meningioma Lawsuits

Many of the women pursuing Depo-Provera lawsuits say their diagnosis came only after extensive medical testing and neurological evaluations to determine the cause of persistent symptoms such as headaches, vision problems, dizziness, hearing loss and cognitive difficulties.

According to allegations raised in lawsuits, women who developed intracranial meningiomas after receiving Depo-Provera injections often undergo a range of diagnostic scans, specialist consultations and long-term monitoring to track tumor growth and determine whether treatment is necessary.

Depo-Provera Federal MDL: Where the Litigation Stands

Amid mounting scientific evidence linking Depo-Provera exposure to intracranial meningioma tumors, and a rapidly growing number of lawsuits nationwide, cases filed in federal court have been centralized into a multidistrict litigation in the U.S. District Court for the Northern District of Florida. 

The coordinated proceedings are being overseen by U.S. District Judge M. Casey Rodgers, who is managing discovery and pretrial issues for claims filed by women across the country.

Since the Depo-Provera litigation was first consolidated, the number of lawsuits has expanded dramatically. Nearly 4,000 cases are now pending in federal and state courts nationwide as of March 2026, a surge from about 1,300 cases in the fall of last year.

In each of the claims being filed, women allege they developed meningioma brain tumors after receiving Depo-Provera birth control injections. Plaintiffs maintain that Pfizer and related defendants failed to adequately warn patients and healthcare providers about the potential tumor risks associated with long-term exposure to medroxyprogesterone acetate.

Depo-Provera Pilot Trials Scheduled for December 2026

As the number of lawsuits continues to grow, Judge Rodgers has directed the parties to prepare a small group of representative cases for early jury trials, often referred to as “pilot” or “bellwether” trials. These cases are selected because they involve facts and injuries that are considered typical of the claims being raised throughout the litigation.

Under the current case management schedule, the first Depo-Provera meningioma trial is expected to begin in December 2026, with additional pilot trials expected to follow if the cases are not resolved beforehand.

These early trials will allow both sides to present scientific evidence and expert testimony about whether long-term exposure to medroxyprogesterone acetate may cause intracranial meningioma tumors. While the verdicts will apply only to the individual plaintiffs whose cases go to trial, the outcomes could help shape settlement discussions, as both plaintiffs and defendants gain a clearer understanding of the strengths and weaknesses of the claims.

Pfizer Argues Depo-Provera Lawsuits Are Preempted by Federal Law

Before the cases move toward trial, the court must resolve a major legal dispute over whether the lawsuits can proceed.

Pfizer first filed a motion for summary judgment in August 2025, arguing that the claims are preempted by federal law, meaning federal drug regulations would override state failure to warn lawsuits. The company says it could not independently add a meningioma warning without FDA approval.

According to court filings, Pfizer first sought to add a meningioma warning in 2023, after a February 2023 epidemiological study involving 25 women linked Depo-Provera injections to intracranial meningiomas, followed by another study in June with similar findings. Pfizer states that its own scientists concluded there was enough evidence of a potential association with long term use to justify a warning and proposed both a label change and an advisory for health care providers.

However, Pfizer says the FDA rejected both proposals, which the company argues means it was legally prohibited from updating the warning label and therefore cannot be held liable under state law. Judge Rodgers is now considering the issue. In January, the court approved a schedule for additional briefing on how the FDA’s recent decision to add a meningioma warning may affect Pfizer’s earlier motion.

Depo-Provera Meningioma Lawsuits Reviewed Nationwide

Women across the United States are now pursuing Depo-Provera lawsuits after being diagnosed with intracranial meningioma tumors following use of the birth control injection.

You may qualify to have your claim reviewed if you meet the following criteria:

• Received Depo-Provera birth control injections
• Later diagnosed with an intracranial meningioma brain tumor

Women pursuing Depo-Provera lawsuits claim the manufacturers failed to adequately warn about the potential risk of developing meningioma tumors associated with prolonged exposure to medroxyprogesterone acetate.

Depo-Provera lawyers are offering free consultations to determine whether affected women may be eligible to pursue financial compensation for medical expenses, lost income and other damages related to a meningioma diagnosis. Claims are typically handled on a contingency fee basis, meaning there are no legal fees unless compensation is recovered.